Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer (AGO-OVAR9)
A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV
Sponsor: AGO Study Group
A PHASE3 clinical study on Fallopian Tube Cancer and Ovarian Cancer, this trial is completed. The trial is conducted by AGO Study Group and has accumulated 8 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2018 [monthly]
Completed PHASE3
First recorded
Aug 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AGO Study Group
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bremen, Germany , Copenhagen, Denmark , Düsseldorf, Germany , Essen, Germany , Frankfurt, Germany , Hanover, Germany , Karlsruhe, Germany , Kiel, Germany , Magdeburg, Germany , Munich, Germany and 6 more locations